Blogs

An interview with Professor John Read who joins us to discuss the UK licensing of esketamine nasal spray (Spravato) for so-called ‘Treatment Resistant Depression’. John led a group of 12 academics and professionals who wrote to the UK regulator expressing concerns.

It took me a long time to realise that I was being gaslighted. In fact, I had no word to describe the experience until years after I had finally escaped, when I came across the term by chance. What is worse, whenever I talk about my past relationship now with friends in my new life, I am horrified to discover how common manipulative relationships are.

The UK’s Medicines & Healthcare Products Regulatory Agency is refusing to respond to the concerns of psychiatrists, parliamentarians, patients and other experts about the impending licensing of the street drug ketamine as a treatment for depression.

What follows is a doctor-patient interaction that I hope will become more commonplace across psychiatric outpatient clinics.

In this ‘identity’ project, we ran a series of workshops exploring different aspects of identity through sculpture, collage, and graphic novel. At the end of each workshop, we gave each group participant the option of sharing their piece with the group and describing both the meaning of the piece and their experience of the creative process.